| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 44.2 | 40.8 |
| Gross profit | 17.2 | 16.4 |
| Profit before tax | -0.7 | -0.2 |
| Net income | -3.5 | -2.9 |
| EPS (diluted, $ a share) | $-0.01 | $-0.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +8.5% |
|---|---|
| Gross margin | 38.8% |
| Operating margin | 2.8% |
10-Q filed with the SEC, OTC: MRMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Marimed Inc.: key numbers
- Share price
- $0.0626Close, Nov 16
- Market cap
- $25.4M
- Shares outstanding
- 406MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Medicinal Chemicals & Botanical ProductsSIC 2833
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Marimed Inc.
All →Marimed Financial Results
MariMed Inc. reported record third-quarter 2026 revenue of $44.2 million, a year-over-year increase driven by growth in both wholesale and retail segments. Despite the revenue growth, the company reported a GAAP net loss of $3.5 million as it continues to execute its 'Expand the Brand' strategy and navigate broader market conditions.
- Term
- Q3 2026
“I’m pleased to report that the momentum we built earlier this year extended through the third quarter. Wholesale and retail revenue both grew sequentially and year over year, and total revenue reached another record for MariMed. Adjusted EBITDA improved from the prior quarter, and we again generated positive cash flow from operations, ending the quarter in our strongest position in more than two years.”
Jon Levine, MariMed’s Chief Executive Officer
Marimed Reverse Stock Split
MariMed stockholders approved a proposal to authorize the board of directors to effect a reverse stock split of its common stock at a ratio between 1-for-50 and 1-for-100. The board retains the discretion to determine the final ratio and timing, or to abandon the split entirely, with the primary goal of potentially meeting listing requirements for a U.S. national securities exchange.
Marimed Reverse Stock Split
MariMed Inc. has filed a definitive proxy statement for a special meeting of stockholders to seek approval for a reverse stock split at a ratio between 1-for-50 and 1-for-100. The move is intended to increase the share price to satisfy listing requirements for a potential move to a major U.S. national securities exchange. The special meeting is scheduled for October 28, 2026.